{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:23Z","timestamp":1793998043602,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05280-9","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T20:35:04Z","timestamp":1686861304000},"page":"2087-2096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution"],"prefix":"10.1007","volume":"102","author":[{"given":"Chethan","family":"R","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender","family":"Sharawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanupriya","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anura","family":"Kantak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-2500","authenticated-orcid":false,"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"5280_CR1","doi-asserted-by":"publisher","first-page":"204062072096612","DOI":"10.1177\/2040620720966120","volume":"11","author":"E Abruzzese","year":"2020","unstructured":"Abruzzese E, Mauro M, Apperley J et al (2020) Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol 11:2040620720966120","journal-title":"Ther Adv Hematol"},{"key":"5280_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JGO.2015.002667","volume":"3","author":"P Ganesan","year":"2017","unstructured":"Ganesan P, Kumar L (2017) Chronic Myeloid Leukemia in India. J Glob Oncol 3:64\u201371","journal-title":"J Glob Oncol"},{"key":"5280_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","volume":"7","author":"J Apperley","year":"2009","unstructured":"Apperley J (2009) Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 7:1050\u20131058","journal-title":"J Natl Compr Canc Netw"},{"key":"5280_CR4","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P et al (2008) The effects of imatinib on pregnancy outcome. Blood 111:5505\u20135508","journal-title":"Blood"},{"key":"5280_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E et al (2015) The impact of dasatinib on pregnancy outcomes. Am J Hematol 90:1111\u20131115","journal-title":"Am J Hematol"},{"key":"5280_CR6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s10815-020-01907-2","volume":"37","author":"SJ Rios","year":"2020","unstructured":"Rios SJ, Mart\u00ednez-Montesinos L, Aroca C et al (2020) Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia. J Assist Reprod Genet 37:2473\u20132476","journal-title":"J Assist Reprod Genet"},{"key":"5280_CR7","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41598-019-39134-0","volume":"9","author":"W Salem","year":"2019","unstructured":"Salem W, Li K, Krapp C et al (2019) Imatinib treatments have long-term impact on placentation and embryo survival. Sci Rep 9:2535","journal-title":"Sci Rep"},{"key":"5280_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10815-020-01778-7","volume":"37","author":"W Salem","year":"2020","unstructured":"Salem W, Ho JR, Woo I et al (2020) Long-term imatinib diminishes ovarian reserve and impacts embryo quality. J Assist Reprod Genet 37:1459\u20131466","journal-title":"J Assist Reprod Genet"},{"key":"5280_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","volume":"16","author":"AM Zamah","year":"2011","unstructured":"Zamah AM, Mauro MJ, Druker BJ et al (2011) Will imatinib compromise reproductive capacity. Oncologist 16:1422\u20131427","journal-title":"Oncologist"},{"issue":"134","key":"5280_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/blood-2019-124430","volume":"13","author":"E Abruzzese","year":"2019","unstructured":"Abruzzese E, Turkina AG, Apperley JF et al (2019) Pregnancy management in CML patients: to treat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) database. Blood 13(134):498","journal-title":"Blood"},{"key":"5280_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"I Madabhavi","year":"2019","unstructured":"Madabhavi I, Sarkar M, Modi M et al (2019) Pregnancy outcomes in chronic myeloid leukemia: a single center experience. J Glob Oncol 5:1\u201311","journal-title":"J Glob Oncol"},{"key":"5280_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/10428194.2020.1849672","volume":"62","author":"R Assi","year":"2021","unstructured":"Assi R, Kantarjian H, Keating M et al (2021) Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62:909\u2013917","journal-title":"Leuk Lymphoma"},{"key":"5280_CR13","first-page":"735","volume":"45","author":"DP Wang","year":"2010","unstructured":"Wang DP, Liang MY, Zhang XH, Wang SM (2010) Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia. Zhonghua Fu Chan Ke Za Zhi 45:735\u2013739","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"5280_CR14","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1634\/theoncologist.2019-0109","volume":"24","author":"X Dou","year":"2019","unstructured":"Dou X, Qin Y, Huang X, Jiang Q (2019) Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. Oncologist 24:e1141\u2013e1147","journal-title":"Oncologist"},{"key":"5280_CR15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","volume":"55","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Ali Z, Khan AU, Aziz Z (2014) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma 55:2109\u20132113","journal-title":"Leuk Lymphoma"},{"key":"5280_CR16","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P et al (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979\u2013981","journal-title":"Haematologica"},{"key":"5280_CR17","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/jcm11071801","volume":"11","author":"E Abruzzese","year":"2022","unstructured":"Abruzzese E, Aureli S, Bondanini F et al (2022) Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases Nilotinib Placental Transfer. J Clin Med 11:1801","journal-title":"J Clin Med"},{"key":"5280_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"5280_CR19","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood-2018-99-119615","volume":"132","author":"J-O Lee","year":"2018","unstructured":"Lee J-O, Kim D-W, Abruzzese E et al (2018) Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis. Blood 132(Supplement 1):4263","journal-title":"Blood"},{"key":"5280_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s13224-015-0682-0","volume":"66","author":"A Patki","year":"2016","unstructured":"Patki A, Chauhan N (2016) An Epidemiology Study to Determine the Prevalence and Risk Factors Associated with Recurrent Spontaneous Miscarriage in India. J Obstet Gynaecol India 66:310\u2013315","journal-title":"J Obstet Gynaecol India"},{"issue":"9","key":"5280_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical Pharmacokinetics of Imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"5280_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2165\/11207770-000000000-00000","volume":"71","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP (2011) Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid Leukaemia in chronic phase. Drugs 71(12):1579\u20131590","journal-title":"Drugs"},{"issue":"7","key":"5280_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C et al (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36(7):1357\u20131364","journal-title":"Drug Metab Dispos"},{"issue":"Supplement 1","key":"5280_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2018-99-118908","volume":"132","author":"E Abruzzese","year":"2018","unstructured":"Abruzzese E, Elena C, Castagnetti F et al (2018) Gimema Registry of Conception\/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood 132(Supplement 1):43","journal-title":"Blood"},{"issue":"6","key":"5280_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/10428190902926973","volume":"50","author":"HG Goh","year":"2009","unstructured":"Goh HG, Kim YJ, Kim DW et al (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 50(6):944\u2013951","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5280_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"key":"5280_CR27","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1038\/s41598-022-09261-2","volume":"12","author":"HM Alkatan","year":"2022","unstructured":"Alkatan HM, Bedaiwi KM, Al-Faky YH et al (2022) Demographics and histopathological characteristics of enucleated microphthalmic globes. Sci Rep 12:5283","journal-title":"Sci Rep"},{"key":"5280_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/bjophthalmol-2016-308952","volume":"101","author":"A Dharmasena","year":"2017","unstructured":"Dharmasena A, Keenan T, Goldacre R et al (2017) Trends over time in the incidence of congenital anophthalmia, microphthalmia and orbital malformation in England: database study. Br J Ophthalmol 101:735\u2013739","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"5280_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","volume":"137","author":"K Ramasamy","year":"2007","unstructured":"Ramasamy K, Hayden J, Lim Z et al (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy [letter]. Br J Haematol 137(4):374\u2013375","journal-title":"Br J Haematol"},{"key":"5280_CR30","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","volume":"351","author":"T Seshadri","year":"2004","unstructured":"Seshadri T, Seymour JF, McArthur GA (2004) Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 351:2134\u20132135","journal-title":"N Engl J Med"},{"key":"5280_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1078155213500686","volume":"20","author":"VS Ghalaut","year":"2014","unstructured":"Ghalaut VS, Prakash G, Bansal P et al (2014) Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report. J Oncol Pharm Pract 20:243\u2013248","journal-title":"J Oncol Pharm Pract"},{"issue":"105","key":"5280_CR32","first-page":"2167","volume":"2","author":"K Bay","year":"2013","unstructured":"Bay K, Bjerrum OW, Olsson-Str\u00f6mberg U et al (2013) Reproductive hormone profiles during imatinib therapy in men with chronic myeloid leukemia. Andrology 2(105):2167\u2013250","journal-title":"Andrology"},{"issue":"6","key":"5280_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","volume":"12","author":"X Chang","year":"2017","unstructured":"Chang X, Zhou L, Chen X et al (2017) Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase. Target Oncol 12(6):827\u2013832","journal-title":"Target Oncol"},{"issue":"40","key":"5280_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/shem.2003.50038","volume":"1","author":"ML Hensley","year":"2003","unstructured":"Hensley ML, Ford JM (2003) Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Semin Hematol 1(40):21\u201325","journal-title":"Semin Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05280-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:06:53Z","timestamp":1689232013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05280-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5280"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05280-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institution review board approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent waiver was granted by the IRB as it was a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}